Idorsia Launches Phase 2 Proof‑of‑Concept Trial for Oral First‑in‑Class Selective CCR6 Antagonist

Idorsia Ltd (SIX: IDIA) has officially started a Phase 2 proof‑of‑concept clinical trial for its oral, first‑in‑class selective CCR6 receptor antagonist, IDOR‑1117‑2520, aiming to explore its potential as a novel therapy for moderate‑to‑severe psoriasis. The trial, conducted in multiple centers and designed as double‑blind, randomized, and placebo‑controlled, will assess whether blocking the CCR6/CCL20 axis can reduce pathogenic immune cell migration and improve clinical outcomes in psoriasis patients over 12 weeks. Key measures will include changes in Psoriasis Area and Severity Index (PASI) and biomarker levels such as beta‑defensin 2. Results are expected in the first quarter of 2027. Psoriasis is a chronic immune‑mediated disease driven by the IL‑23/Th17 pathway, with elevated levels of CCR6‑positive cells in affected skin. By inhibiting CCR6, IDOR‑1117‑2520 aims to prevent Th17 cells from reaching inflamed tissues, offering an oral alternative to existing injectable therapies that target the same pathway. If successful, this trial could validate CCR6 antagonism as a therapeutic approach and open development into other CCR6‑ and Th17‑associated autoimmune disorders. Senior Idorsia executives highlighted the compelling potential of this oral therapy to deliver biologic‑like efficacy and validated proof‑of‑mechanism across Th17‑driven diseases. Approximately 30 participants will be randomized to receive one of two doses or placebo once daily. #Idorsia #CCR6 #Psoriasis #AutoimmuneTherapy #SlimScan #GrowthStocks #CANSLIM